Acute Kidney Injury Treated with Dialysis outside the Intensive Care Unit: A Retrospective Observational Single-Center Study.
BACKGROUND
The number of patients suffering from acute kidney injury requiring dialysis (AKI-D) is increasing. Whereas causes and outcome of AKI-D in the intensive care unit (ICU) are described extensively, few data exist about AKI-D patients treated outside the ICU. Aim of this study was to identify the causes of AKI-D, determine in-depth the comorbid conditions and outcome of this particular patient group and identify possibilities for its prevention.


METHODS
We retrospectively studied all AKI-D patients treated outside the ICU in a single nephrology referral center between January 2010 and June 2015. Data on comorbid conditions, renal function and drug therapy prior to AKI-D, and possible causal events were collected. Patients were grouped into those with renal hypoperfusion as the predominant cause of AKI-D (hemodynamic group) and those with other causes (non-hemodynamic group).


RESULTS
During 66 months 128 patients (57% male, mean age 69.3 years) were treated. AKI-D was community-acquired in 70.3%. The most frequent comorbidities were hypertension (62.5%), chronic kidney disease (CKD) (58.9%), coronary artery disease (CAD) (46.1%), diabetes (35.9%) and heart failure (34.1%). Most patients were prescribed diuretics (61.7%) and inhibitors of the renin-angiotensin-aldosterone system (RASI) (57.8%); 46.1% had a combination of both. In the 88 patients with hemodynamic AKI-D (68.8%) the most frequent initiating events were diarrhea (39.8%), infections (17.0%) and acute heart failure (13.6%). In the 40 patients with non-hemodynamic AKI-D (31.2%) interstitial nephritis (n = 15) was the prominent diagnosis. Patients with hemodynamic AKI-D were older (72.6 vs. 62.1 years, p = 0.001), suffered more often from CKD (68.2% vs. 33.3%, p = 0.003), CAD (54.5% vs. 27.5%, p = 0.004) and diabetes (42.0% vs. 22.5%, p = 0.033), and were more frequently on diuretics (75.0% vs. 32.5%, p<0.001), RASI (67.0% vs. 37.5%, p = 0.002) or their combination (58.0% vs. 20.0%, p<0.001). Twenty-two (17.2%) patients died and 27 (21.1%) patients died or developed end-stage renal disease.


CONCLUSIONS
AKI-D treated outside the ICU is most often caused by renal hypoperfusion. It predominantly afflicts elderly patients with one or more comorbid conditions, who are treated with diuretics and RASI and have an acute illness leading to volume depletion. Early discontinuation of these drugs may be a successful strategy to avoid AKI-D in vulnerable patients.
Department of Nephrology and Dialysis, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.|Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
Hannelore
H
Sprenger-Mähr
Department of Nephrology and Dialysis, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.|Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
Emanuel
E
Zitt
Department of Nephrology and Dialysis, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.|Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
Karl
K
Lhotta
Crit Care. 2008;12(3):R74
18533029
Nephrol Dial Transplant. 2015 Sep;30(9):1472-9
25324356
Am J Kidney Dis. 2012 Sep;60(3):402-8
22541737
Kidney Int. 2012 Mar;81(5):477-85
22157656
J Am Soc Nephrol. 2005 Nov;16(11):3365-70
16177006
J Am Soc Nephrol. 2013 Jan;24(1):37-42
23222124
Nat Rev Nephrol. 2010 Aug;6(8):461-70
20517290
J Am Soc Nephrol. 2007 Apr;18(4):1292-8
17314324
N Engl J Med. 2008 Jul 3;359(1):7-20
18492867
Med J Aust. 2000 Feb 21;172(4):184-5
10772593
Clin J Am Soc Nephrol. 2016 Jan 7;11(1):14-20
26683890
Nephrol Dial Transplant. 2007 Sep;22(9):2513-9
17517795
Crit Care. 2013 Feb 04;17(1):205
23394215
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1007-14
24677557
Clin J Am Soc Nephrol. 2013 Sep;8(9):1482-93
23744003
PLoS One. 2013 Nov 06;8(11):e78465
24223154
J Am Soc Nephrol. 2016 Mar;27(3):914-23
26134154
Fundam Clin Pharmacol. 2014 Apr;28(2):230-5
23190210
Kidney Int. 2015 Nov;88(5):1161-9
26221750
QJM. 2002 Sep;95(9):579-83
12205335
PLoS One. 2016 Feb 10;11(2):e0148809
26863015
Lancet. 2013 Jul 13;382(9887):170-9
23727171
J Nephrol. 2015 Jun;28(3):339-49
24935754
Int J Cardiol. 2013 Oct 9;168(4):4386-7
23711447
BMC Nephrol. 2014 May 29;15:84
24885247
Nat Rev Nephrol. 2010 Feb;6(2):107-15
20027192
Nephrol Dial Transplant. 2010 Jun;25(6):1833-9
20054022
Am J Kidney Dis. 2005 Mar;45(3):531-9
15754275
Kidney Int. 2009 Oct;76(8):893-9
19641480
N Engl J Med. 2009 Oct 22;361(17):1627-38
19846848
Am J Epidemiol. 2000 Mar 1;151(5):488-96
10707917
BMJ. 2013 Jan 08;346:e8525
23299844
JAMA. 2005 Aug 17;294(7):813-8
16106006
Kidney Int. 2012 Mar;81(5):442-8
22113526
PLoS One. 2015 Apr 16;10(4):e0122899
25880729
Kidney Int. 2015 Aug;88(2):396-403
25874600
Lancet. 2012 Aug 25;380(9843):756-66
22617274
J Am Med Dir Assoc. 2014 Oct;15(10):719-24
24814042